Drug Discovery · Boston, MA · Founded 2025 · Privately Held (backing)
Operator of a clinical-stage biotechnology company intended to develop novel therapies for pulmonary arterial hypertension through innovative molecular mechanisms. PAhR Therapeutics is based in Boston, MA and was founded in 2025. It was valued at $25 million at its seed round in Jul 2025, the last priced event on record. It has raised $14 million across 1 recorded round; the latest was a $14 million seed round in Jul 2025.
PMV mark · valuation
$25.0M
Oct 2026
Priced at
its seed round
Jul 2025
Total raised
$14.0M
Last round
Seed Round
Jul 2025
No prints on record
No secondary trades in PAhR Therapeutics shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of PAhR Therapeutics with a free account
·Watch PAhR Therapeutics: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of PAhR Therapeutics stock.
